Last updated: June 7, 2026
Executive summary
- The IV combination dextrose 2.5% + sodium chloride 0.9% (commonly supplied as a D5/NS-like solution in a plastic bag/container) is typically sourced through US sterile injectable manufacturers that fill and package premixed, ready-to-infuse solutions.
- Key supplier qualification points for this specific presentation are plastic container type (bag), container size, concentration match (2.5% dextrose, 0.9% NaCl), sterility assurance (aseptic processing), and supply channel (GPO/wholesale/contract manufacturing).
Who supplies IV “dextrose 2.5% + sodium chloride 0.9%” in plastic containers?
There is no single global supplier list that is stable across container types, package sizes, and national markets. In practice, supply comes from manufacturers that produce sterile, premixed IV solutions and package them in flexible plastic containers (and, in some cases, via parallel distributors).
US supply channels that typically carry this product
- Wholesale distributors (McKesson, Cardinal Health, AmerisourceBergen) distribute finished sterile injectables, including dextrose-saline premixes, to hospitals and IDNs.
- GPO-backed hospital supply contracts often determine which named manufacturer is used at a given facility.
- Specialty distributors may carry scarce sterile products during shortages.
Manufacturing/filling archetypes to map supplier lists
Suppliers you should track fall into three groups:
- Premix solution manufacturers that produce the formulation and fill into plastic bags.
- Contract sterile manufacturers (CMOs) that fill for branded or relabeled product owners.
- Repackagers/parallel importers in some jurisdictions, which can change the labeled manufacturer without changing the formulation.
What suppliers make dextrose/saline premixed solutions in plastic bags?
Premixed IV dextrose-saline solutions in plastic containers are produced by sterile injectable plants with capability for:
- Aseptic mixing/filling
- Container integrity testing and release testing
- Labeling, NDC assignment (for US-facing brands), and distribution
Examples of supplier types to target (by footprint)
Use these manufacturer archetypes when building a supplier slate:
- Large US sterile injectable firms with broad IV premix portfolios
- Global sterile injectables companies with US packaging capacity
- Regional sterile injectables makers with plastic-container IV lines
How do you identify the exact product match for “dextrose 2.5% and sodium chloride 0.9%” (vs lookalikes)?
This combination is often confused with other common IV mixes:
- dextrose 5% in 0.9% sodium chloride (D5/NS, not 2.5% dextrose)
- dextrose 2.5% in water for injection (D2.5W)
- dextrose 10% saline variations
- lactated formulations (D5LR vs D5/NS)
What must match on the label and spec sheet
- Dextrose concentration: 2.5%
- Sodium chloride concentration: 0.9%
- Container system: plastic bag/container
- Sterility: sterile, single-dose (typical for IV bags)
- Osmolality and electrolytes if listed
- Total volume (for example 250 mL, 500 mL, 1000 mL, depending on market)
Screening fields for procurement and quality teams
- NDC (US), product code, and manufacturer name
- Certificate of Analysis (CoA) and package configuration
- Expiration dating and storage conditions (often controlled room temperature)
- Container size and overwrap details
Which companies provide this product through wholesalers or hospital contracts?
If you need a practical procurement-ready view, suppliers should be mapped in two layers:
- Wholesaler stocking source (who can deliver quickly)
- Manufacturer of record (who actually produced/filled/packaged)
Wholesaler layer (delivery and availability)
US hospital purchasers typically see supply via:
- Cardinal Health
- McKesson
- AmerisourceBergen
These entities may carry multiple manufacturers for the same NDC across time.
Contract layer (stable named suppliers)
Hospital systems and GPOs often keep a primary supplier list, then switch sources during supply constraints.
What Orange Book or FDA listing checks matter for this IV solution?
Most premixed IV solutions are regulated as sterile drug products with an FDA listing in databases tied to application holders (for branded/generic labeling). For supplier validation, the critical checks are:
- FDA drug listing (active ingredient and dosage form match)
- NDC-to-manufacturer mapping
- Facility inspection history for sterile injectable manufacturing sites (as part of quality review)
What should procurement verify in supplier qualification for plastic-container IV dextrose-saline?
For this specific presentation, the supplier due diligence package usually includes:
Product quality and stability
- CoA for the delivered lot (assay, pH, osmolality if specified)
- Stability data for the labeled shelf-life
- Compatibility statements for typical IV administration workflows
Container and administration risk controls
- Plastic bag type and seal integrity
- Leak testing and visual inspection process
- Compatibility with common infusion sets and tubing
Compliance and supply continuity
- GMP compliance status and sterile facility controls
- Batch release testing controls
- Backup manufacturing/packaging sites
How many suppliers typically exist, and what creates supply risk?
In sterile IV premix markets, the supplier count is often limited by:
- specialized aseptic filling capacity
- high regulatory and validation burden
- procurement concentration at GPOs
- episodic shortages tied to plant downtime or raw material constraints
Supply risk increases when:
- the product is in limited package sizes
- the formulation is only produced by a subset of plants
- there is a shortage of a specific plastic container SKU or component
What generic entry or relabeling scenarios affect supplier lists?
Even if the formulation is “simple,” supplier lists can shift due to:
- manufacturer changes in the labeled product
- relabeling for private-label hospital brands
- different NDC configurations for the same concentration
- short-term sourcing switches by distributors
Key takeaways
- Treat “dextrose 2.5% + sodium chloride 0.9% in plastic container” as a specific labeled product match, not a generic class.
- Supplier identification must be anchored to NDC/product code, manufacturer of record, and container configuration.
- Build a supplier slate in two steps: distribution availability (wholesalers/contract channels) and manufacturing origin (filled/packaged by whom).
- Qualification should focus on aseptic sterile process controls, container integrity, CoA confirmation for lot release, and stability/expiry alignment.
FAQs
- How do I confirm the concentration is truly 2.5% dextrose and 0.9% NaCl (not D5/NS or D2.5W)?
- Which database field should I use to map NDCs to the manufacturer of record for sterile IV premixes?
- What plastic container attributes matter for IV compatibility and leak risk in dextrose-saline solutions?
- What supplier qualification documents are mandatory for lot-level release decisions (CoA, sterility/USP tests, container integrity)?
- How do wholesalers typically handle substitution during IV shortage events for premixed dextrose-saline bags?
References
- FDA. “Drug Listing Data.” US Food and Drug Administration. (Accessed via FDA drug listing databases).
- FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” US Food and Drug Administration. (Accessed via Orange Book database).
- USP. “General Chapters for Sterile Preparations and Container Closure.” United States Pharmacopeia. (Accessed via USP publications).
